Dexamethasone alters plasma levels of beta-endorphin and postoperative pain

Kenneth M Hargreaves, Elizabeth A. Schmidt, Gregory P. Mueller, Raymond A. Dionne

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Secretion of pituitary immunoreactive β-endorphin is hypothesized to modulate the perception of pain. The present study examined this question by evaluating the effects of intravenous placebo or dexamethasone (0.1, 0.32, or 1.0 mg) on suppression of immunoreactive β-endorphin secretion and development of postoperative pain after the surgical removal of impacted third molars in 48 patients. Compared with placebo, all doses of dexamethasone suppressed the postoperative increase in circulating levels of immunoreactive β-endorphin. Patients administered 0.1 mg dexamethasone reported greater levels of pain, compared with those given placebo, from 60 through 120 minutes after surgery. Postoperative pain for the 0.32 and 1.0 mg doses did not differ from that for the placebo group. The increased pain after suppression of β-endorphin release by the low dose of dexamethasone suggests that pituitary secretion of immunoreactive β-endorphin alleviates postoperative pain under these conditions.

Original languageEnglish (US)
Pages (from-to)601-607
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume42
Issue number6
StatePublished - Dec 1987
Externally publishedYes

Fingerprint

Endorphins
beta-Endorphin
Postoperative Pain
Dexamethasone
Placebos
Pain
Placebo Effect
Pain Perception
Third Molar

ASJC Scopus subject areas

  • Pharmacology

Cite this

Dexamethasone alters plasma levels of beta-endorphin and postoperative pain. / Hargreaves, Kenneth M; Schmidt, Elizabeth A.; Mueller, Gregory P.; Dionne, Raymond A.

In: Clinical Pharmacology and Therapeutics, Vol. 42, No. 6, 12.1987, p. 601-607.

Research output: Contribution to journalArticle

Hargreaves, Kenneth M ; Schmidt, Elizabeth A. ; Mueller, Gregory P. ; Dionne, Raymond A. / Dexamethasone alters plasma levels of beta-endorphin and postoperative pain. In: Clinical Pharmacology and Therapeutics. 1987 ; Vol. 42, No. 6. pp. 601-607.
@article{7b4df2cb91044afabf4fded8ea76ced7,
title = "Dexamethasone alters plasma levels of beta-endorphin and postoperative pain",
abstract = "Secretion of pituitary immunoreactive β-endorphin is hypothesized to modulate the perception of pain. The present study examined this question by evaluating the effects of intravenous placebo or dexamethasone (0.1, 0.32, or 1.0 mg) on suppression of immunoreactive β-endorphin secretion and development of postoperative pain after the surgical removal of impacted third molars in 48 patients. Compared with placebo, all doses of dexamethasone suppressed the postoperative increase in circulating levels of immunoreactive β-endorphin. Patients administered 0.1 mg dexamethasone reported greater levels of pain, compared with those given placebo, from 60 through 120 minutes after surgery. Postoperative pain for the 0.32 and 1.0 mg doses did not differ from that for the placebo group. The increased pain after suppression of β-endorphin release by the low dose of dexamethasone suggests that pituitary secretion of immunoreactive β-endorphin alleviates postoperative pain under these conditions.",
author = "Hargreaves, {Kenneth M} and Schmidt, {Elizabeth A.} and Mueller, {Gregory P.} and Dionne, {Raymond A.}",
year = "1987",
month = "12",
language = "English (US)",
volume = "42",
pages = "601--607",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Dexamethasone alters plasma levels of beta-endorphin and postoperative pain

AU - Hargreaves, Kenneth M

AU - Schmidt, Elizabeth A.

AU - Mueller, Gregory P.

AU - Dionne, Raymond A.

PY - 1987/12

Y1 - 1987/12

N2 - Secretion of pituitary immunoreactive β-endorphin is hypothesized to modulate the perception of pain. The present study examined this question by evaluating the effects of intravenous placebo or dexamethasone (0.1, 0.32, or 1.0 mg) on suppression of immunoreactive β-endorphin secretion and development of postoperative pain after the surgical removal of impacted third molars in 48 patients. Compared with placebo, all doses of dexamethasone suppressed the postoperative increase in circulating levels of immunoreactive β-endorphin. Patients administered 0.1 mg dexamethasone reported greater levels of pain, compared with those given placebo, from 60 through 120 minutes after surgery. Postoperative pain for the 0.32 and 1.0 mg doses did not differ from that for the placebo group. The increased pain after suppression of β-endorphin release by the low dose of dexamethasone suggests that pituitary secretion of immunoreactive β-endorphin alleviates postoperative pain under these conditions.

AB - Secretion of pituitary immunoreactive β-endorphin is hypothesized to modulate the perception of pain. The present study examined this question by evaluating the effects of intravenous placebo or dexamethasone (0.1, 0.32, or 1.0 mg) on suppression of immunoreactive β-endorphin secretion and development of postoperative pain after the surgical removal of impacted third molars in 48 patients. Compared with placebo, all doses of dexamethasone suppressed the postoperative increase in circulating levels of immunoreactive β-endorphin. Patients administered 0.1 mg dexamethasone reported greater levels of pain, compared with those given placebo, from 60 through 120 minutes after surgery. Postoperative pain for the 0.32 and 1.0 mg doses did not differ from that for the placebo group. The increased pain after suppression of β-endorphin release by the low dose of dexamethasone suggests that pituitary secretion of immunoreactive β-endorphin alleviates postoperative pain under these conditions.

UR - http://www.scopus.com/inward/record.url?scp=0023598070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023598070&partnerID=8YFLogxK

M3 - Article

C2 - 2961501

AN - SCOPUS:0023598070

VL - 42

SP - 601

EP - 607

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -